Pharmacogenomic Drug-Gene Interactions in Geriatric Emergency Department Patients That Have Fallen

Introduction

As individuals age, they have more medical problems and are prescribed more medications. Taking more than five medications, i.e., polypharmacy, leads to increased adverse drug events (ADEs), hospitalizations and poor outcomes [1–4]. Of these poor outcomes, falling and fall-related injury are among the most important [1,5].

Stopping a medication, i.e., deprescribing, is a very difficult process [6]. Although several methods for medication assessment and possible discontinuation have been published, most have not been widely adopted and there are many challenges associated with stopping medications [7–11]. Pharmacogenomic tests may provide an objective method for physicians to identify medications that are high risk for ADE and allow them to deprescribe or prescribe medications more precisely and appropriately. The objective of this study was to assess pharmacogenomic drug-gene interactions in geriatric ED patients that have fallen. This may provide the basis for pharmacogenomic-guided medication prescribing in older patients at risk for fall related injury.

Methods

Results

Twenty-five patients were enrolled. The median age was 81 years (IQR: 76-85) and 68% were female. The most frequent co-morbidities were hypertension (64%), atrial fibrillation (32%), coronary artery disease (28%) and stroke (8%).

All patients were on medications for pre-existing co-morbidities (see Table 2). Patients were taking a median of 8 medications (IQR: 5-11). The most common types were antihypertensives, statins, anticoagulants, and anti-platelet medications. All the patients had suffered a fall, as this was part of the inclusion criteria. Most had contusions, fractures and wounds. Several also had significant medical problems such as stroke, head injury and syncope (see Table 3).

When considering the pharmacogenomic data and drug-gene interactions, of our 25 patients, 14/25 (56%) had one or more Yellow or Red medications (see figure 1) for a total of 20 significant gene-drug interactions (see Table 4). Further, 6/25 (24%) had one or more Red medications identified (see Figure 1). The implicated medications were those that could increase risk of falling with several drugs with the potential for increased sedation (escitalopram, tramadol, trazodone, oxycodone and duloxetine) and others potentially causing bradycardia or hypotension (metoprolol and amlodipine).

• Download figure
• Open in new tab

Figure 1. Possible drug-gene medication interactions for each patient

Discussion

As an individual gets older, they develop more medical problems and are prescribed more medicines. The more medications that someone takes, the higher the risk for an ADE [16]. Polypharmacy, taking five or more medicines is a major risk factor for an ADE [17].

Shaver et. al. in 2021 showed that mortality risk in older United States (US) persons from falls increased steadily from 1999 to 2017, as the use of Fall Risk Increasing Drugs (FRIDs) increased. During that period, the percentage of older people taking a FRIDs increased from 57% to 97% [3].

On average, 750 US older adults are hospitalized each day due to an ADE and 50% are taking seven or more medications [5,11]. Further, about 60% of older people have one or more medicines that are unnecessary [18]. Among geriatric ED patients about 75% have one or more medications that are classified as “avoid” or “use with caution [6].”

However, stopping a medication (deprescribing) has proven to be very difficult for patients and physicians [11]. Although a number of methods for medication assessment and possible discontinuation have been published, most have not been widely adopted [7–9,15,19]. Deprescribing presents several significant challenges in clinical practice including doctors lacking training in stopping medications, doctors worrying about worsening symptoms, patients worrying about worsening symptoms, concern for withdrawal, the time required to discuss medication changes, and patients feeling like their doctor is “giving up” and no longer treating their disease [11,12,20].

Pharmacogenomics may provide an objective means to help with this problem. It is a genetic means to assess for possible risk of ADEs and may one day become standard information for physicians to help provide more precise and personalized prescribing of medications. Pharmacogenomics involves gene testing to assess how an individual metabolizes medications. Hepatic enzymes in the P450 systems (i.e. CYPD6, CYP3A4, CYP2C19) are responsible for metabolizing many commonly used medications (i.e. Lipitor®, Valium®, warfarin, Xarelto®, Zoloft®, and many others). In addition, CYP2D6 has many different genetic polymorphisms and depending on the inherited alleles the individual CYP2D6 system may function as poor, intermediate, extensive or ultrarapid metabolizers [21].

Most people are intermediate and extensive metabolizers and in our current system of dosing medications, a “one size fits all” approach, the standard dose will provide concentrations in the therapeutic window predictably. However, if they are a poor metabolizer or ultrarapid metabolizer, a given medication may be in the toxic or ineffective concentration range.

In our study each patient’s medications was assessed for a potential for a drug-gene interaction based on DNA Labs pharmacogenomic report. Of our 25 patients, there were a total of 20 (Red or Yellow) significant potential drug-gene interactions identified with 56% having one or more Yellow or Red medications (see Figure and 5). In addition, 20% had at least one red drug-gene medication interaction identified. Examples of significant gene-drug interactions include:

• Reduced CYP2D6 enzyme activity in someone taking metoprolol. These individuals are poor metabolizers of metoprolol and have a three-to-ten-fold higher concentration compared to an extensive metabolizer. Further, poor metabolizers had a five times higher rate of ADE compared to non-poor metabolizers. These ADE include symptomatic bradycardia and dizziness [22].

• Reduced CYP2C19 enzyme activity in someone taking clopidogrel. Approximately 30% of individuals taking clopidogrel have reduced or zero CYP2C19 activity which leads to decreased platelet inhibition effect and worse cardiovascular outcomes [23].

An additional important finding is that many of the gene-drug interactions that were identified are not on the American Geriatrics Society 2023 updated AGS Beers Criteria® (see Table 4) [15]. The medication involved in 11 of the 20 (55%) significant potential drug-gene interactions are not on this Beers list. The Beers Criteria® is a list of potentially inappropriate medications for older adults. It is developed by a panel of interprofessional experts who review the published literature to establish this list. This list does not appear to reflect potential drug-gene medication interactions, as more than 50% of the medicines involved in interactions identified in our study were not on the Beers list.

Conclusions

In geriatric ED patients that present for a fall-related injury, a majority have a significant pharmacogenomic drug-gene interactions. DNA testing can identify these interactions and can assist with pharmacogenomic-guided medication prescribing, which has the potential to decrease ADEs and improve clinical outcomes.

Declaration of Sources of Funding

This study was supported by a grant from the Florida Medical Malpractice Joint Underwriting Association Grant for Safety of Health Care Services Grant RFA #2022-01. “The Geriatric Emergency Department Fall Injury Prevention (The GREAT FALL).” Principal Investigator: Richard D. Shih MD. The funding sources had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and the decision to submit the manuscript for publication.